Novartis announces delivery of one billion courses of anti-malarial treatment

Novartis announced today that it has delivered one billion courses of antimalarial treatment since 1999. More than 90 per cent of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries around the globe, it said.

Working with Chinese partners, Novartis launched the first fixed-dose ACT (artemether-lumefantrine) in 1999. Artemisinin is a natural compound found in the plant Artemisia annua, or sweet wormwood, and has shown to clear malaria parasites in the blood. ACTs combine an artemisinin derivative with a partner drug to reduce the risk of resistance if artemisinin is given alone.

Adoption of ACTs as first-line treatment by the World Health Organization (WHO) has been critical to the global malaria response. Since 2000, the WHO estimates that 1.5 billion malaria cases have been averted and 7.6 million lives saved. Along with malaria prevention tools and better diagnostics, ACTs remain a key component of the global drive to reach malaria elimination.

In 2001, two years after the launch of its ACT, Novartis signed an agreement with the WHO, committing to make the antimalarial available without profit to the public sector of malaria-endemic countries. The company informed that though the agreement expired in 2011, it continues to provide treatments on the same terms as before.

“This is a landmark moment in the fight against malaria. Over the last 20 years, Novartis has delivered one billion treatments in more than 70 countries. We could not have achieved this milestone without the support of our global partners and those we work with on the ground in endemic countries,” said Dr Lutz Hegemann, Group Head, Corporate Affairs and Global Health, Novartis.

In a statement, the company informed, “Children bear a significant burden of malaria disease and death. This led Novartis and Medicines for Malaria Venture (MMV) to partner on the development of the first dispersible ACT formulated specifically for children. Of the one billion treatments delivered, more than 430 million are the pediatric formulation launched in 2009.”

The company is now testing a new ACT formulation for infants weighing less than five kilograms in collaboration with the PAMAfrica research consortium led by MMV. This is one of the most vulnerable groups affected by malaria, for whom there is currently no approved treatment.

In 2018, Novartis committed to invest more than $100 million over five years to further advance research and development of next-generation treatments.

Novartis currently leads five malaria development programs worldwide, featuring three compounds that employ new mechanisms of action and activity against artemisinin-resistant strains of the disease.

KAF156 (ganaplacide) belongs to a novel class of antimalarial compounds that act against both the blood and liver stages of the parasite’s lifecycle. It demonstrated activity against both P. vivax and P. falciparum malaria, including artemisinin-resistant parasites. Novartis leads the development of this compound with scientific and financial support from MMV and from EDCTP via the WANECAM2 Consortium.

KAE609 (cipargamin) is another novel antimalarial compound demonstrating rapid clearance of parasites pre-clinically and in patients. Novartis is leading the development of KAE609 with financial support from the Wellcome Trust and in collaboration with the PAMAFRICA Consortium supported by EDCTP and led by MMV.

In 2020, the company discovered another novel malaria compound, INE963, which has an entirely new mechanism of action which will begin clinical trials in 2021. INE963 is a fastacting, long-lasting antimalarial which holds promise for a high barrier to resistance. It was discovered with support from MMV and received the organization’s “Project of the Year” award in 2020.